SMN2 and proximal spinal muscular atrophy: Research efforts are underway to develop both SMN‐dependent and SMN‐independent therapies for improved and sustained benefit and to clinically evaluate the safety and efficacy of combinatorial approaches in SMA patients (NCT04488133, NCT03032172).